Medicine and Surgery Respiratory Module updated following release of new NICE guidance on Asthma

4th December 2024

We have recently split the Respiratory Medicine module within our Medicine and Surgery SCRIPT portfolio into two modules, titled: ‘Respiratory Medicine: Oxygen, Smoking Cessation and Inhalers’ and ‘Respiratory Medicines: Asthma and Croup’.

The two new modules cover the same content as the original module, but in a more digestible and focused format. Splitting the module into two has been timed to coincide with the release of the new NICE guideline “Asthma: diagnosis, monitoring and chronic asthma management”. 

The modules now reflect the newly published guideline that a low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler (e.g., Symbicort 200/6 Turbohaler®) is recommended on a when required basis for adults and children aged 12 and over. This is a significant change in clinical practice as, historically, salbutamol would have been used.

More News

SCRIPT eLearning Shortlisted for Prestigious HSJ Patient Safety Award

SCRIPT eLearning is delighted to announce that it has been shortlisted in the ‘Patient Safety Education and Training’ category of the HSJ Patient Safety Awards 2026, recognising its ongoing contribution to improving safety in prescribing and medicines management. The...

Birmingham Education for Health Professional Conference 2026

The SCRIPT team was delighted to present a poster at the Birmingham Education for Health Professional Conference 2026, led by our Research Associate Divya Singh. The poster, titled "eLearning in Multidisciplinary Prescribing Education: A Longitudinal Evaluation...

New Modules Under Development

We are committed to developing and adding new modules to ensure the SCRIPT programme continues to reflect current clinical practice and meets our learners’ changing needs. We have several modules at various stages of development, including Drugs of Addiction and...

Updated module – Diabetes: Antihyperglycaemic Medicines

NICE has recently updated its guidance on ‘Type 2 diabetes in adults: management’. In a change to national guidance modified‑release metformin alongside an SGLT2 inhibitor is now recommended as first‑line treatment for adults with type 2 diabetes mellitus....